This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Constantinescu, C S Articles by Kappos, L Search for Related Content PubMed PubMed Citation Articles by Constantinescu, C S Articles by Kappos, L Social Bookmarking                   What's this?

Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis

Division of Clinical Neurology, University Hospital, Queen's Medical Centre, Nottingham NG7 2UH, UK, Department of Neurology, University Hospitals Basle, 4031 Basle, Switzerland

P Freitag

Department of Neurology, University Hospitals Basle, 4031 Basle, Switzerland

L Kappos

Department of Neurology, University Hospitals Basle, 4031 Basle, Switzerland

Free radicals including peroxynitrite are induced in Multiple Sclerosis (MS). Antioxidant and peroxynitrite inhibitor uric acid (UA), suppresses the MS animal model experimental autoimmune encephalomyelitis (EAE). MS patients have lower average serum UA than controls. An inverse relationship exists between MS and gout. Glatiramer acetate (GA) suppresses EAE and is beneficial in relapsing MS. We investigated serum UA changes during open-label treatment of relapsing MS with GAA. Ten patients (six females, four males, aged 19 to 39 years, mean age 32 years) completed 6 months of GAA (Copaxone® 20 mg s.c. daily). Of these, nine completed 12 months. After 6 months on GAA, serum UA (normal, 173-359 mmol/ml for women, 258-491 mmol/ml for men) increased in nine and marginally decreased (302 to 300 mmol/ml) in a single patient. Mean UA significantly increased from 240 to 303 mol/ml (P=0.0014). At 12 months, UA remained significantly higher than at start (P=0.006) decreasing in only one patient. In contrast, we found no significant UA changes after 6 and 12 months of treatment in 21 MS patients treated with interferon b1-a (Avonex®), or in 11 treated with interferon b1-a (Rebif®), or in five placebo-treated controls. Increasing UA, a natural inhibitor of free radicals, may represent a mechanism of action of glatiramer acetate in MS.

Key Words: glatiramer acetate • multiple sclerosis • uric acid • peroxynitrite • reactive nitrogen intermediates • reactive oxygen intermediates

Multiple Sclerosis, Vol. 6, No. 6, 378-381 (2000)
DOI: 10.1177/135245850000600603


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C M Knapp, C S Constantinescu, J H. Tan, R McLean, G R Cherryman, and I Gottlob Serum uric acid levels in optic neuritis Multiple Sclerosis, June 1, 2004; 10(3): 278 - 280. [Abstract] [PDF]